AU2007231547B2 - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU2007231547B2
AU2007231547B2 AU2007231547A AU2007231547A AU2007231547B2 AU 2007231547 B2 AU2007231547 B2 AU 2007231547B2 AU 2007231547 A AU2007231547 A AU 2007231547A AU 2007231547 A AU2007231547 A AU 2007231547A AU 2007231547 B2 AU2007231547 B2 AU 2007231547B2
Authority
AU
Australia
Prior art keywords
selenate
tau
pp2a
disease
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007231547A
Other languages
English (en)
Other versions
AU2007231547A1 (en
Inventor
Niall Corcoran
Christopher Hovens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velacor Therapeutics Pty Ltd
Original Assignee
Velacor Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velacor Therapeutics Pty Ltd filed Critical Velacor Therapeutics Pty Ltd
Publication of AU2007231547A1 publication Critical patent/AU2007231547A1/en
Assigned to VELACOR THERAPEUTICS PTY LTD reassignment VELACOR THERAPEUTICS PTY LTD Alteration of Name(s) of Applicant(s) under S113 Assignors: CORCORAN, NIALL, HOVENS, CHRISTOPHER
Application granted granted Critical
Publication of AU2007231547B2 publication Critical patent/AU2007231547B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2007231547A 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases Ceased AU2007231547B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78724006P 2006-03-29 2006-03-29
US60/787,240 2006-03-29
PCT/AU2007/000391 WO2007109851A1 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2007231547A1 AU2007231547A1 (en) 2007-10-04
AU2007231547B2 true AU2007231547B2 (en) 2012-07-12

Family

ID=38540722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007231547A Ceased AU2007231547B2 (en) 2006-03-29 2007-03-29 Treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (2) US8920851B2 (OSRAM)
EP (1) EP2004204B1 (OSRAM)
JP (1) JP5542430B2 (OSRAM)
KR (1) KR101451439B1 (OSRAM)
CN (1) CN101478977B (OSRAM)
AU (1) AU2007231547B2 (OSRAM)
BR (1) BRPI0709033A2 (OSRAM)
CA (1) CA2644441C (OSRAM)
DK (1) DK2004204T3 (OSRAM)
ES (1) ES2394348T3 (OSRAM)
MX (1) MX2008012479A (OSRAM)
NZ (2) NZ596244A (OSRAM)
RU (1) RU2489155C2 (OSRAM)
WO (1) WO2007109851A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067008B2 (en) 2004-08-23 2011-11-29 Yeda Research And Development Co. Peptide inhibitors for mediating stress responses
NZ596244A (en) 2006-03-29 2013-05-31 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
JP5616631B2 (ja) * 2006-04-24 2014-10-29 オルテック インコーポレイテッド 細胞機能を変化させるための方法および組成物
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
WO2008119109A1 (en) 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
WO2009039586A2 (en) * 2007-09-28 2009-04-02 Powmri Limited Biomarkers for parkinson's disease
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis
WO2009043116A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Methods and compositions for the treatment of phosphatase- related disorders
US20100247517A1 (en) * 2007-11-22 2010-09-30 Boehringer Ingelheim Internationational GmbH Use of mnk inhibitors for the treatment of alzheimer's disease
JP5328244B2 (ja) * 2008-07-07 2013-10-30 株式会社ニュージェン・ファーマ 筋萎縮性側索硬化症治療剤
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
JP6659050B2 (ja) * 2015-03-26 2020-03-04 スーヂョウ アウゾン バイオロジカル テクノロジー カンパニー， リミテッド Ｐ７５ｅｃｄ及び／又はｐ７５による神経学的障害の診断又は処置方法
WO2019216589A1 (ko) * 2018-05-09 2019-11-14 한국과학기술연구원 타우 관련 질환의 예방 또는 치료용 조성물
KR102846956B1 (ko) * 2018-06-29 2025-08-14 리주베나떼 바이오메드 엔브이 노화-관련 질환 및/또는 퇴행성 질환에 사용하는 약제학적 결합물
CA3131402A1 (en) * 2019-03-26 2020-10-01 Xiaoyan Zhao Compositions, methods and systems for protein corona analysis from biofluids and uses thereof
WO2023029210A1 (zh) * 2021-08-31 2023-03-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍
WO2023057422A1 (en) * 2021-10-06 2023-04-13 Bayer Aktiengesellschaft Universal buffer in methods for safe and rapid detection of pathogen infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810497A (en) * 1986-01-27 1989-03-07 Efamol Limited Pharmaceutical compositions
WO2003066071A1 (en) * 2002-02-07 2003-08-14 Laxdale Limited Formulations comprising psychotropic drugs and selenium
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
AU2005227420A1 (en) * 2005-10-14 2007-05-03 Alltech, Inc. Method and compositions for altering cell function

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04247033A (ja) * 1991-02-04 1992-09-03 Yoshitomi Pharmaceut Ind Ltd 神経細胞壊死抑制剤
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
DE10059886A1 (de) 2000-12-01 2002-06-20 Basf Coatings Ag Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen
CA2495386C (en) * 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
WO2004099168A2 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
AU2003904328A0 (en) 2003-08-13 2003-08-28 Garvan Institute Of Medical Research Diagnosis and treatment of neurodegenerative disorders
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US20050142216A1 (en) 2003-12-31 2005-06-30 Rindlesbach Keith A. Method for reversing Alzheimer dementia
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
NZ596244A (en) 2006-03-29 2013-05-31 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
WO2007109853A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810497A (en) * 1986-01-27 1989-03-07 Efamol Limited Pharmaceutical compositions
US6746678B1 (en) * 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
WO2003066071A1 (en) * 2002-02-07 2003-08-14 Laxdale Limited Formulations comprising psychotropic drugs and selenium
US20030175361A1 (en) * 2002-02-07 2003-09-18 Vaddadi Krishnarao Sitaramrao Novel formulations of drugs
AU2005227420A1 (en) * 2005-10-14 2007-05-03 Alltech, Inc. Method and compositions for altering cell function

Also Published As

Publication number Publication date
RU2489155C2 (ru) 2013-08-10
WO2007109851A1 (en) 2007-10-04
CA2644441A1 (en) 2007-10-04
CN101478977A (zh) 2009-07-08
EP2004204A1 (en) 2008-12-24
US20090169649A1 (en) 2009-07-02
EP2004204A4 (en) 2010-06-02
NZ596244A (en) 2013-05-31
US20140141104A1 (en) 2014-05-22
JP5542430B2 (ja) 2014-07-09
RU2008142514A (ru) 2010-05-10
JP2009532340A (ja) 2009-09-10
EP2004204B1 (en) 2012-09-12
CN101478977B (zh) 2013-03-27
KR101451439B1 (ko) 2014-10-16
US8920851B2 (en) 2014-12-30
DK2004204T3 (da) 2013-01-07
CA2644441C (en) 2014-09-09
MX2008012479A (es) 2009-08-13
AU2007231547A1 (en) 2007-10-04
ES2394348T3 (es) 2013-01-30
BRPI0709033A2 (pt) 2011-06-21
KR20090015038A (ko) 2009-02-11
NZ571835A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
CA2644441C (en) Treatment of neurodegenerative diseases
ES2402365T3 (es) Uso de compuestos de selenio, especialmente levaduras de selenio, para modificar la función cognitiva
JP5616631B2 (ja) 細胞機能を変化させるための方法および組成物
US20110038889A1 (en) Methods and compositions for altering cell function
Malavolta et al. Trace elements and minerals in health and longevity
JP4684553B2 (ja) 生理学的過程の調節およびこれに有用な薬剤
US8865763B2 (en) Methods and compositions for altering cell function
WO2008119109A1 (en) Treatment of neurological disorders
US8871715B2 (en) Use of selenium compounds, especially selenium yeasts for altering cognitive function
US20100247679A1 (en) Methods and compositions for altering cell function
US20070155687A1 (en) Methods and compositions for altering cell function
Park et al. Protective effects of phosphodiesterase 5 inhibitor, mirodenafil, on traumatic brain injury-induced neuron death
Da Silva et al. D‐2‐Hydroxyglutaric acid inhibits creatine kinase activity from cardiac and skeletal muscle of young rats
AU2013205053B2 (en) Method and compositions for altering cell function
Quinn EFFECTS OF SELENIUM ON SELENOPROTEINS AND BRAIN DAMAGE AFTER ISCHEMIA IN GERBILS
Morgan-Bathke The role of autophagy in salivary gland dysfunction following targeted head and neck radiation
Henkel The effects of a heterozygous SOD2-deficiency and running exercise on the knee articular cartilage in a mouse model
David Convergence of Dopamine and NMDAR Signaling on MAPK and Regulation of Protein Translation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired